Jack Phan1, Terence T Sio2, Theresa P Nguyen1, Vinita Takiar3, G Brandon Gunn1, Adam S Garden1, David I Rosenthal1, Clifton D Fuller1, William H Morrison1, Beth Beadle1, Dominic Ma1, Mark E Zafereo4, Kate A Hutcheson5, Michael E Kupferman4, William N William6, Steven J Frank7. 1. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Radiation Oncology, Mayo Clinic, Scottsdale, Arizona. 3. Department of Radiation Oncology, University of Cincinnati, Cincinnati, Ohio. 4. Department of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas. 5. Department of Speech Pathology University of Texas MD Anderson Cancer Center, Houston, Texas. 6. Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 7. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: sjfrank@mdanderson.org.
Abstract
PURPOSE: Reirradiation of head and neck (H&N) cancer is a clinical challenge. Proton radiation therapy (PRT) offers dosimetric advantages for normal tissue sparing and may benefit previously irradiated patients. Here, we report our initial experience with the use of PRT for H&N reirradiation, with focus on clinical outcomes and toxicity. METHODS AND MATERIALS: We retrospectively reviewed the records of patients who received H&N reirradiation with PRT from April 2011 through June 2015. Patients reirradiated with palliative intent or without prior documentation of H&N radiation therapy were excluded. Radiation-related toxicities were recorded according to the Common Terminology Criteria for Adverse Events Version 4.0. RESULTS: The conditions of 60 patients were evaluated, with a median follow-up time of 13.6 months. Fifteen patients (25%) received passive scatter proton therapy (PSPT), and 45 (75%) received intensity modulated proton therapy (IMPT). Thirty-five patients (58%) received upfront surgery, and 44 (73%) received concurrent chemotherapy. The 1-year rates of locoregional failure-free survival, overall survival, progression-free survival, and distant metastasis-free survival were 68.4%, 83.8%, 60.1%, and 74.9%, respectively. Eighteen patients (30%) experienced acute grade 3 (G3) toxicity, and 13 (22%) required a feeding tube at the end of PRT. The 1-year rates of late G3 toxicity and feeding tube independence were 16.7% and 2.0%, respectively. Three patients may have died of reirradiation-related effects (1 acute and 2 late). CONCLUSIONS: Proton beam therapy can be a safe and effective curative reirradiation strategy, with acceptable rates of toxicity and durable disease control.
PURPOSE: Reirradiation of head and neck (H&N) cancer is a clinical challenge. Proton radiation therapy (PRT) offers dosimetric advantages for normal tissue sparing and may benefit previously irradiated patients. Here, we report our initial experience with the use of PRT for H&N reirradiation, with focus on clinical outcomes and toxicity. METHODS AND MATERIALS: We retrospectively reviewed the records of patients who received H&N reirradiation with PRT from April 2011 through June 2015. Patients reirradiated with palliative intent or without prior documentation of H&N radiation therapy were excluded. Radiation-related toxicities were recorded according to the Common Terminology Criteria for Adverse Events Version 4.0. RESULTS: The conditions of 60 patients were evaluated, with a median follow-up time of 13.6 months. Fifteen patients (25%) received passive scatter proton therapy (PSPT), and 45 (75%) received intensity modulated proton therapy (IMPT). Thirty-five patients (58%) received upfront surgery, and 44 (73%) received concurrent chemotherapy. The 1-year rates of locoregional failure-free survival, overall survival, progression-free survival, and distant metastasis-free survival were 68.4%, 83.8%, 60.1%, and 74.9%, respectively. Eighteen patients (30%) experienced acute grade 3 (G3) toxicity, and 13 (22%) required a feeding tube at the end of PRT. The 1-year rates of late G3 toxicity and feeding tube independence were 16.7% and 2.0%, respectively. Three patients may have died of reirradiation-related effects (1 acute and 2 late). CONCLUSIONS: Proton beam therapy can be a safe and effective curative reirradiation strategy, with acceptable rates of toxicity and durable disease control.
Authors: Christina A Wicker; Brian G Hunt; Sunil Krishnan; Kathryn Aziz; Shobha Parajuli; Sarah Palackdharry; William R Elaban; Trisha M Wise-Draper; Gordon B Mills; Susan E Waltz; Vinita Takiar Journal: Cancer Lett Date: 2021-01-12 Impact factor: 8.679
Authors: Linton T Evans; Franco DeMonte; David R Grosshans; Amol J Ghia; Ahmed Habib; Shaan M Raza Journal: J Neurol Surg B Skull Base Date: 2019-02-21
Authors: Sulsal Haque; Vidhya Karivedu; Muhammed K Riaz; David Choi; Logan Roof; Sarah Z Hassan; Zheng Zhu; Roman Jandarov; Vinita Takiar; Alice Tang; Trisha Wise-Draper Journal: Oral Oncol Date: 2018-11-16 Impact factor: 5.337
Authors: Kenneth C W Wong; Edwin P Hui; Kwok-Wai Lo; Wai Kei Jacky Lam; David Johnson; Lili Li; Qian Tao; Kwan Chee Allen Chan; Ka-Fai To; Ann D King; Brigette B Y Ma; Anthony T C Chan Journal: Nat Rev Clin Oncol Date: 2021-06-30 Impact factor: 66.675
Authors: Jimmy J Caudell; Matthew C Ward; Nadeem Riaz; Sara J Zakem; Musaddiq J Awan; Neal E Dunlap; Derek Isrow; Comron Hassanzadeh; John A Vargo; Dwight E Heron; Samuel Marcrom; Drexell H Boggs; Chandana A Reddy; Joshua Dault; James A Bonner; Kristin A Higgins; Jonathan J Beitler; Shlomo A Koyfman; Mitchell Machtay; Min Yao; Andy M Trotti; Farzan Siddiqui; Nancy Y Lee Journal: Int J Radiat Oncol Biol Phys Date: 2017-12-01 Impact factor: 7.038
Authors: Alexander F Bagley; Adam S Garden; Jay P Reddy; Amy C Moreno; Steven J Frank; David I Rosenthal; William H Morrison; Gary Brandon Gunn; Clifton D Fuller; Shalin J Shah; Renata Ferrarotto; Erich M Sturgis; Neil D Gross; Jack Phan Journal: Head Neck Date: 2020-08-09 Impact factor: 3.147